Braun Stacey Associates Inc. Sells 101,873 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 16th, 2023

Braun Stacey Associates Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 80.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,494 shares of the company’s stock after selling 101,873 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Johnson & Johnson were worth $3,797,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Moneta Group Investment Advisors LLC increased its holdings in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter worth $4,609,399,000. Morgan Stanley increased its holdings in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after buying an additional 3,849,148 shares during the last quarter. Finally, Savant Capital LLC increased its holdings in Johnson & Johnson by 8,568.8% during the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after buying an additional 3,588,251 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 in the last quarter. 0.20% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $172.92 on Wednesday. The company has a market capitalization of $449.41 billion, a PE ratio of 35.00, a P/E/G ratio of 2.92 and a beta of 0.54. The company has a 50 day simple moving average of $165.50 and a two-hundred day simple moving average of $161.20. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.59 EPS. Research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on JNJ shares. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Atlantic Securities upped their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target on the stock. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, July 31st. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Hold” and an average price target of $171.80.

Read Our Latest Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.